Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE)
Latest Information Update: 15 May 2024
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms RADAR; RADAR (UK-MRA Myeloma XV)
Most Recent Events
- 12 Dec 2023 Trial design, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing patient-reported outcomes from participants enrolling in the RADAR study to understand the HRQoL of MM patients in different subgroups prior to treatment, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 13 Dec 2022 Trial design presented at the 64th American Society of Hematology Annual Meeting and Exposition